As a vital receptor of bradykinin, BDKRB2 has been widely reported in a range of malignancies, including cervical cancer [10], triple-negative breast cancer [11], hepatocellular carcinoma (HCC) [12, 13], gastric cancer [14–16], colorectal cancer [17], prostate cancer [18], bladder cancer [19], head and neck squamous cell carcinomas [20], and chondrosarcoma [21]. This evidence concerns the gene BDKRB2 and prostate carcinoma.